Share this article
Share this article
The subsidiary provides CDMO services, utilizing 57,000 sq. ft. of laboratory space and cutting-edge process chemistry technology in Princeton South, New Jersey and Richmond, Virginia.
KOLKATA, India, Feb. 4, 2021 /PRNewswire/
TCG GreenChem provides high-end, integrated CMC services covering development to cGMP clinical trial supplies
TCG GreenChem will accelerate the transition of drug candidates through the development pipeline efficiently and economically utilizing innovative catalysis and continuous flow chemistry technologies
TCG GreenChem will be seamlessly integrated with TCG Lifesciences India operations to serve its global customers across the full range of discovery, development, and commercial applications
TCG Greenchem (PRNewsfoto/TCG Lifesciences Pvt. Ltd.)
Share this article
The subsidiary provides CDMO services, utilizing 57,000 sq. ft. of laboratory space and cutting-edge process chemistry technology in Princeton South, New Jersey and Richmond, Virginia.
KOLKATA, India, Feb. 4, 2021 /PRNewswire/
TCG GreenChem provides high-end, integrated CMC services covering development to cGMP clinical trial supplies
TCG GreenChem will accelerate the transition of drug candidates through the development pipeline efficiently and economically utilizing innovative catalysis and continuous flow chemistry technologies
TCG GreenChem will be seamlessly integrated with TCG Lifesciences India operations to serve its global customers across the full range of discovery, development, and commercial applications
TCG Greenchem
TCG Lifesciences Pvt. Ltd., a company controlled by New York-based The Chatterjee Group ( TCG ), has announced today the expansion of its operations in the USA with the establishment of TCG GreenChem Inc., a subsidiary of TCG Li
Tendinitis Treatment Market Sales Insights, Industry Dynamics, Size Estimation, Growth Statistics, Business Overview and COVID-19 Impact Analysis By 2023
Lupin rose 2.12% to Rs 1,021.80 after the company said that it received a tentative approval for its Empagliflozin and Metformin Hydrochloride ER tablets from the US drug regulator.
The drug is a generic equivalent of Synjardy XR tablets of Boehringer Ingelheim Pharmaceuticals Inc. The product will be manufactured at Lupin s Nagpur (Maharashtra) facility in India.
The drug is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes mellitus when treatment with both empaglifiozin and metformin hydrochloride is appropriate.
As per IQVIA MAT November 2020 data, Empagliflozin and Metformin Hydrochloride ER tablets (RLD: Synjardyt XR) had estimated annual sales of $357 million in the US. The announcement was made during market hours today, 7 January 2021.